
Sarepta Therapeutics said Friday that it intends seek regulators’ approval for its gene therapy to treat Duchenne muscular dystrophy earlier than expected — a risky move but one that could help the company reach the market much faster.
In early Friday trading, Sarepta shares rose 12% to $96.50.
Create a display name to comment
This name will appear with your comment